 U.S.-listed shares of Zealand Pharma ZEAL, 1.83 ZEAL, 18.99 soared 21.2 in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment for babies with a rare genetic disorder met the primary endpoint. Zealand is testing dasiglucagon as a treatment for pediatric patients with congenital hyperinsulinism, which causes excess insulin secretion and low blood sugar. 